Equity Field Notes from temporal sources

[DanWebzster]

TNXP is presently in a Ph3 study of their lead treatment for military PTSD-related symptoms (nightmares and insomnia)

Tonmya is a sublingual intended to block an adrenergic receptor associated with nightmares. In Ph2, it showed a dose response relationship but did not meet the primary endpoint.

A significant side-effect of Tonmya is severe oral numbness

The active ingredient for Tonmya is also available in a generic pill.

Tonmya is also entering a Ph2 study for agitation in Alzheimer disease, where there are no competing treatments. The problem here is that the tongue/oral numbness side effect may derail its commercial viability.

With the company's recently announced $75mn-secondary, TNXP has a cash runway into the middle of 2020.